Początki medycyny nuklearnej w Europie. The development of Nuclear Medicine in Europe.

Artykuł przedstawia początki Medycyny Nuklearnej jako jednej najintensywniej ewoluujących dziedzin medycyny, fizyki, chemii oraz inżynierii medycznej. Europejska medycyna nuklearna, ze względu na podłoże historyczne i polityczne, mające duży wpływ na kształtowanie się wszystkich gałęzi nauki na kontynencie, należy bez wątpienia do jednego najciekawszych wątków w medycynie światowej. Złożoność genezy i ewolucji medycyny nuklearnej stanowi doskonały przykład kreatywności europejskich badaczy.This article describes Nuclear Medicine as one of most intensively developing medical, physical, chemical and engineering field of science. European Nuclear Medicine as undoubtedly one of most interesting topics in the medical world, deserves closer attention because of its complex historical and political origin which had great influence on establishing the branch of science on the continent.

7th International Congress of the Croatian Society of Nuclear Medicine

SummaryThe Seventh International Congress of The Croatian Society of Nuclear Medicine gives an overview of present-day nuclear medicine. For the Congress 82 papers were selected: 50 for oral and 32 for poster presentation. Of 82 accepted papers 44 came from Croatia. Other papers came from Austria, Bosnia and Herzegovina, Germany, Greece, Hungary, Italy, Kosovo, Russia, Slovenia and Serbia. There were 16 lectures as part of CME programme. The congress shows that Croatian nuclear medicine follows general trends of the European nuclear medicine. This report includes a selection of abstracts that might interest the readers of Nuklearmedizin.

The Joint Task Group on Clinical Utility of Labelled Antibodies of the Society of Nuclear Medicine Europa (Snme) and the European Nuclear Medicine Society (Enms)

In September 1985 a task group on the clinical utility of labelled antibodies was founded by the Society of Nuclear Medicine - Europe. This document was elaborated to report the aims and the programs of the group. In September 1986 the European Nuclear Medicine Society decided to partecipate in this initiative and a joint task group was created. Initial Document A. The aims ot the Task Group are to monitor, co-ordinate and promote research and clinical application of techniques using radiolabeled antibodies in nuclear medicine. A.1. The Group should develop into a major point of reference, giving scientific and technical support to each member of the Society involved in this field. B. To pursue these purposes it will be necessary to develop the following: B.1. Criteria to evaluate the suitability of antigen-antibody systems for tumour detection and/or therapy. B. 2. Criteria for quality control of radioimmunoreagents. B. 3. Criteria for the prevention of adverse reactions or damage due to the reagent. B. 4. Selection of suitable dosimetric methods for diagnostic or therapeutic applications. B. 5. Elaboration of protocols for clinical experiments, including appropriate techniques to be applied in single cases. B. 6. Organization of cooperative studies. C. The Task Group should promote: C.1. Informal meetings between the members of the Group. C.2. Workshops open to the members of the Society and other researchers. C.3. Publication of reports in appropriate journals.